Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $66,629.39 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 34,523 shares of the business’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $1.93, for a total value of $66,629.39. Following the completion of the transaction, the chief executive officer directly owned 482,744 shares in the company, valued at approximately $931,695.92. This represents a 6.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Joseph Oliveto also recently made the following trade(s):

• On Monday, December 15th, Joseph Oliveto sold 133,054 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.32, for a total value of $308,685.28.
• On Thursday, January 8th, Joseph Oliveto sold 43,000 shares of Milestone Pharmaceuticals stock. The stock was sold at an average price of $2.25, for a total transaction of $96,750.00.
• On Wednesday, January 7th, Joseph Oliveto sold 500 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $2.25, for a total transaction of $1,125.00.

Milestone Pharmaceuticals Price Performance

Shares of MIST stock opened at $1.91 on Friday. Milestone Pharmaceuticals Inc. has a 1 year low of $0.63 and a 1 year high of $3.06. The company has a current ratio of 8.24, a quick ratio of 8.24 and a debt-to-equity ratio of 2.74. The firm’s 50 day moving average is $2.22 and its 200-day moving average is $1.97. The firm has a market capitalization of $162.67 million, a price-to-earnings ratio of -2.33 and a beta of 0.44.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.05. Sell-side analysts forecast that Milestone Pharmaceuticals Inc. will post -0.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Propel Bio Management LLC increased its position in shares of Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock valued at $10,250,000 after buying an additional 3,333,333 shares in the last quarter. Orbimed Advisors LLC acquired a new position in Milestone Pharmaceuticals in the third quarter valued at about $6,444,000. Simplify Asset Management Inc. increased its holdings in shares of Milestone Pharmaceuticals by 186.2% in the third quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock worth $5,666,000 after acquiring an additional 1,842,974 shares in the last quarter. Pathstone Holdings LLC acquired a new stake in shares of Milestone Pharmaceuticals during the third quarter worth about $2,000,000. Finally, Boxer Capital Management LLC bought a new position in shares of Milestone Pharmaceuticals during the 3rd quarter valued at about $1,333,000. 86.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

MIST has been the subject of several recent research reports. TD Cowen raised Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, December 15th. Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Wells Fargo & Company raised their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Zacks Research upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 26th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.00.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.